Morgan Stanley upgraded Merck citing improved pipeline prospects and raised price targets, while RBC downgraded the stock due to elevated valuation despite stronger-than-expected data, seeing balanced risk and future growth depending on more clinical successes.
Merck stock upgraded at Morgan Stanley; RBC downgrades (MRK)
